We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Lexology logo






  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 16

Experimental evidence comply with the rules or risk inadmissibility

  • King & Wood Mallesons
  • -
  • Australia
  • -
  • March 22 2013

By refusing to allow Generic Health to adduce experimental evidence in a patent case currently being heard in the Federal Court, Justice Jagot has

Blockbuster drug goes bust? The Federal Court finds three AstraZeneca patents relating to Crestor (rosuvastatin) invalid

  • King & Wood Mallesons
  • -
  • Australia
  • -
  • March 7 2013

In an important decision handed down on Tuesday, Justice Jagot of the Federal Court held that three patents relating to the blockbuster drug Crestor

Homeopathy plus! Not immune from the ACL

  • King & Wood Mallesons
  • -
  • Australia
  • -
  • March 7 2013

On 21 February 2013, the ACCC instituted proceedings against Homeopathy Plus! Australia Pty Ltd ("Homeopathy Plus!") in the Federal Court of

Australian court decides important gene patenting question isolated genetic material patentable subject matter

  • King & Wood Mallesons
  • -
  • Australia
  • -
  • February 15 2013

Earlier today, the Federal Court rejected a claim brought by Cancer Voices Australia that isolated genetic material (DNA or RNA) that is naturally

Those drugs cost how much?? Chemist warehouse price list misleading but not for the reasons you might think

  • King & Wood Mallesons
  • -
  • Australia
  • -
  • October 29 2012

Last Monday the Supreme Court of Queensland held that a price list published by various Chemist Warehouse pharmacies in Cairns, Nerang, Coolangatta and other parts of Queensland was likely to mislead or deceive and therefore contravene clause 18 of the Australian Consumer Law (Competition and Consumer Act 2010 (Cth), schedule 2, section 18

European Commission ups the cost of paying for delay

  • King & Wood Mallesons
  • -
  • Australia, European Union, USA
  • -
  • August 13 2012

On 25 July 2012, the EC alleged that Danish pharmaceutical company Lundbeck violated EU antitrust rules by colluding to prevent other pharma companies from marketing generic versions of its best-seller antidepressant, citalopram

Vioxx class action: special leave refused

  • King & Wood Mallesons
  • -
  • Australia
  • -
  • July 10 2012

On 15 May 2012 the High Court refused special leave to appeal from the decision of the Full Federal Court to refuse to award damages in the Vioxx class action

Special leave to appeal refused in the VIOXX class action

  • King & Wood Mallesons
  • -
  • Australia
  • -
  • July 5 2012

The High Court of Australia has refused special leave to appeal from the full court of the Federal Court of Australia in the VIOXX class action

Federal Court prescribes hard medicine for Vioxx class action

  • King & Wood Mallesons
  • -
  • Australia
  • -
  • March 15 2012

The full court of the Federal Court of Australia recently overturned a damages award in the VIOXX class action, confirming once again that issues of causation are no less difficult to prove in large-scale class actions than in individual proceedings

ACCC joins NRM to Advanced Medical Institute proceedings, alleging unfair contract terms

  • King & Wood Mallesons
  • -
  • Australia
  • -
  • November 3 2011

On 7 September 2011, the ACCC announced that the Federal Court had granted orders to add NRM Corporation Pty Ltd and NRM Trading Pty Ltd as respondents in the ACCC’s existing case against Advanced Medical Institute for alleged unconscionable conduct

Current Search

Suggested Facets

Author

Jurisdiction

Workarea

© Copyright 2006-2013 Globe Business Publishing Ltd | Cookies | Disclaimer | Privacy policy